Cover Image
市場調查報告書

食道癌:開發中產品分析

Esophageal Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229727
出版日期 內容資訊 英文 493 Pages
訂單完成後即時交付
價格
Back to Top
食道癌:開發中產品分析 Esophageal Cancer - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 493 Pages
簡介

食道癌是食道發病的癌症之一。主要的症狀有咳嗽和吞嚥障礙,胸部疼痛,壓迫感或加熱感,體重減少等。

本報告提供全球各國治療食道癌所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

食道癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

食道癌:企業開發中的治療藥

食道癌:大學/機關研究中的治療藥

食道癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

食道癌:企業開發中的產品

食道癌:大學/機關研究中的產品

食道癌的治療藥的開發企業

  • Adaptimmune Therapeutics Plc
  • Advantagene, Inc.
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • Almac Discovery Limited
  • Amgen Inc.
  • ArQule, Inc.
  • Array BioPharma Inc.
  • Aslan Pharmaceuticals Pte. Ltd.
  • ATLAB Pharma SAS
  • Bayer AG
  • Betta Pharmaceuticals Co. Ltd.
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Cellectar Biosciences, Inc.
  • Cerulean Pharma, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Genmab A/S
  • Glycotope GmbH
  • Hutchison MediPharma Limited
  • Ignyta, Inc.
  • ImmunoFrontier, Inc.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • Komipharm International Co., Ltd.
  • MacroGenics, Inc.
  • Mebiopharm Co., Ltd.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Omeros Corporation
  • Omnitura Therapeutics Inc.
  • Oncolys BioPharma Inc.
  • 小野藥品工業
  • Pfizer Inc.
  • Proteo, Inc.
  • Puma Biotechnology, Inc.
  • Shenzen SiBiono GeneTech Co., Ltd.
  • 鹽野義製藥
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Symphogen A/S
  • Synta Pharmaceuticals Corp.
  • 大鵬藥品工業
  • Taiwan Liposome Company, Ltd.
  • TaKaRa BIO
  • tella Inc
  • TG Therapeutics, Inc.
  • Transgene Biotek Limited
  • VioQuest Pharmaceuticals, Inc.
  • Virocan Therapeutics Private Limited

食道癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

食道癌:最近的開發平台趨勢

食道癌:暫停中的計劃

食道癌:開發中止的產品

食道癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9205IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H1 2017, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 33, 28, 2, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 5, 2 and 1 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Esophageal Cancer - Overview
    • Esophageal Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Esophageal Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Esophageal Cancer - Companies Involved in Therapeutics Development
    • Adaptimmune Therapeutics Plc
    • ADC Therapeutics Sarl
    • Aduro BioTech Inc
    • Advaxis Inc
    • Advenchen Laboratories LLC
    • Almac Discovery Ltd
    • Amgen Inc
    • Aprea AB
    • ArQule Inc
    • Array BioPharma Inc
    • Aslan Pharmaceuticals Pte Ltd
    • ATLAB Pharma SAS
    • Bayer AG
    • BeiGene Ltd
    • Beta Pharma Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • CBT Pharmaceuticals Inc
    • Celgene Corp
    • Celldex Therapeutics Inc
    • Cellectar Biosciences Inc
    • CellSeed Inc
    • Clovis Oncology Inc
    • Cyclacel Pharmaceuticals Inc
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Genmab A/S
    • GlaxoSmithKline Plc
    • Glycotope GmbH
    • Hutchison China MediTech Ltd
    • Ignyta Inc
    • Immunocore Ltd
    • ImmunoFrontier Inc
    • Immunomedics Inc
    • Intezyne Technologies Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • Johnson & Johnson
    • Komipharm International Co Ltd
    • Leap Therapeutics Inc
    • MaxiVAX SA
    • Mebiopharm Co Ltd
    • MedImmune LLC
    • Merck & Co Inc
    • Novartis AG
    • Omeros Corp
    • Oncolys BioPharma Inc
    • OncoMed Pharmaceuticals Inc
    • Ono Pharmaceutical Co Ltd
    • Puma Biotechnology Inc
    • Rhizen Pharmaceuticals SA
    • Shionogi & Co Ltd
    • Spectrum Pharmaceuticals Inc
    • Stelic Institute & Co Inc
    • Supratek Pharma Inc
    • Symphogen A/S
    • Taiho Pharmaceutical Co Ltd
    • Taiwan Liposome Company Ltd
    • Takara Bio Inc
    • Transgene Biotek Ltd
    • VioQuest Pharmaceuticals Inc
    • XuanZhu Pharma Co Ltd
  • Esophageal Cancer - Drug Profiles
    • (tipiracil hydrochloride + trifluridine) - Drug Profile
    • 1-BB1 - Drug Profile
    • ADCT-502 - Drug Profile
    • ADXS-HER2 - Drug Profile
    • afatinib dimaleate - Drug Profile
    • AL-3818 - Drug Profile
    • ALM-301 - Drug Profile
    • apatinib - Drug Profile
    • APR-246 - Drug Profile
    • atezolizumab - Drug Profile
    • ATL-101 - Drug Profile
    • BGBA-317 - Drug Profile
    • binimetinib - Drug Profile
    • brontictuzumab - Drug Profile
    • CBT-501 - Drug Profile
    • CDX-1401 - Drug Profile
    • Cellular Immunotherapy 1 for Esophageal Cancer - Drug Profile
    • Cellular Immunotherapy for Esophageal Cancer - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile
    • Cellular Immunotherapy to Target EPCAM for Oncology - Drug Profile
    • Cellular Immunotherapy to Target HER-2 for Advanced Malignancy and Metastatic Cancer - Drug Profile
    • Cellular Immunotherapy to Target MAGEA4 for Oncology - Drug Profile
    • Cellular Immunotherapy to Target NY-ESO 1 for Oncology - Drug Profile
    • cetuximab biobetter - Drug Profile
    • CGX-1321 - Drug Profile
    • CLS-2702C - Drug Profile
    • CRS-207 - Drug Profile
    • CYC-140 - Drug Profile
    • DKN-01 - Drug Profile
    • donafenib - Drug Profile
    • doxorubicin - Drug Profile
    • durvalumab - Drug Profile
    • elgemtumab - Drug Profile
    • erdafitinib - Drug Profile
    • futuximab + modotuximab - Drug Profile
    • ganetespib - Drug Profile
    • GSK-2256098 - Drug Profile
    • GSK-3359609 - Drug Profile
    • GSK-3377794 - Drug Profile
    • HKT-288 - Drug Profile
    • HMPL-309 - Drug Profile
    • I131-CLR1404 - Drug Profile
    • IBI-308 - Drug Profile
    • icotinib hydrochloride - Drug Profile
    • IMF-001 - Drug Profile
    • ipilimumab + nivolumab - Drug Profile
    • IT-139 - Drug Profile
    • JNJ-63723283 - Drug Profile
    • JS-001 - Drug Profile
    • KML-001 - Drug Profile
    • LY-3143921 - Drug Profile
    • MEDI-3622 - Drug Profile
    • Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile
    • MVXONCO-1 - Drug Profile
    • neratinib - Drug Profile
    • nimotuzumab - Drug Profile
    • nintedanib - Drug Profile
    • nivolumab - Drug Profile
    • OBP-301 - Drug Profile
    • oxaliplatin - Drug Profile
    • paclitaxel albumin bound - Drug Profile
    • panitumumab - Drug Profile
    • pasireotide ER - Drug Profile
    • PCA-062 - Drug Profile
    • pembrolizumab - Drug Profile
    • pralatrexate - Drug Profile
    • Recombinant Protein 1 for Oncology - Drug Profile
    • rucaparib camsylate - Drug Profile
    • RXDX-106 - Drug Profile
    • S-222611 - Drug Profile
    • S-588410 - Drug Profile
    • sacituzumab - Drug Profile
    • SDS-eCAR - Drug Profile
    • SHR-1210 - Drug Profile
    • sirotinib - Drug Profile
    • Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile
    • Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile
    • SMYD2-BAY02 - Drug Profile
    • STNM-01 - Drug Profile
    • TBI-1201 - Drug Profile
    • TBL-0805E - Drug Profile
    • TGR-1202 - Drug Profile
    • tisotumab vedotin - Drug Profile
    • tivantinib - Drug Profile
    • TLC-388 - Drug Profile
    • triciribine phosphate - Drug Profile
    • Vaccine for Advanced Squamous Cell Carcinoma of Esophagus and Adenocarcinoma of Colon - Drug Profile
    • Vaccine for Oncology - Drug Profile
    • Vaccine for Oncology - Drug Profile
    • varlitinib - Drug Profile
    • VIMO-001 - Drug Profile
    • YQ-23 - Drug Profile
  • Esophageal Cancer - Dormant Projects
  • Esophageal Cancer - Discontinued Products
  • Esophageal Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Esophageal Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
  • Esophageal Cancer - Pipeline by ADC Therapeutics Sarl, H1 2017
  • Esophageal Cancer - Pipeline by Aduro BioTech Inc, H1 2017
  • Esophageal Cancer - Pipeline by Advaxis Inc, H1 2017
  • Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Esophageal Cancer - Pipeline by Almac Discovery Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Amgen Inc, H1 2017
  • Esophageal Cancer - Pipeline by Aprea AB, H1 2017
  • Esophageal Cancer - Pipeline by ArQule Inc, H1 2017
  • Esophageal Cancer - Pipeline by Array BioPharma Inc, H1 2017
  • Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
  • Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H1 2017
  • Esophageal Cancer - Pipeline by Bayer AG, H1 2017
  • Esophageal Cancer - Pipeline by BeiGene Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Beta Pharma Inc, H1 2017
  • Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Esophageal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Esophageal Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Esophageal Cancer - Pipeline by Celgene Corp, H1 2017
  • Esophageal Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Esophageal Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
  • Esophageal Cancer - Pipeline by CellSeed Inc, H1 2017
  • Esophageal Cancer - Pipeline by Clovis Oncology Inc, H1 2017
  • Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Esophageal Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Genmab A/S, H1 2017
  • Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Esophageal Cancer - Pipeline by Glycotope GmbH, H1 2017
  • Esophageal Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Ignyta Inc, H1 2017
  • Esophageal Cancer - Pipeline by Immunocore Ltd, H1 2017
  • Esophageal Cancer - Pipeline by ImmunoFrontier Inc, H1 2017
  • Esophageal Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Esophageal Cancer - Pipeline by Intezyne Technologies Inc, H1 2017
  • Esophageal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Johnson & Johnson, H1 2017
  • Esophageal Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Leap Therapeutics Inc, H1 2017
  • Esophageal Cancer - Pipeline by MaxiVAX SA, H1 2017
  • Esophageal Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
  • Esophageal Cancer - Pipeline by MedImmune LLC, H1 2017
  • Esophageal Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Esophageal Cancer - Pipeline by Novartis AG, H1 2017
  • Esophageal Cancer - Pipeline by Omeros Corp, H1 2017
  • Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H1 2017
  • Esophageal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
  • Esophageal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
  • Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
  • Esophageal Cancer - Pipeline by Shionogi & Co Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Esophageal Cancer - Pipeline by Stelic Institute & Co Inc, H1 2017
  • Esophageal Cancer - Pipeline by Supratek Pharma Inc, H1 2017
  • Esophageal Cancer - Pipeline by Symphogen A/S, H1 2017
  • Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Esophageal Cancer - Pipeline by Takara Bio Inc, H1 2017
  • Esophageal Cancer - Pipeline by Transgene Biotek Ltd, H1 2017
  • Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals Inc, H1 2017
  • Esophageal Cancer - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
  • Esophageal Cancer - Dormant Projects, H1 2017
  • Esophageal Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Esophageal Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Esophageal Cancer - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Esophageal Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top